Eli Lilly projects 32% revenue growth for 2025, fueled by incretin expansion and new launches
Q4 2024 Management View CEO David Ricks highlighted a 45% revenue growth in Q4, with significant contributions from Mounjaro and Zepbound. He emphasized ongoing expansion in manufacturing to meet ...
Diabetes and obesity drugs fuel Eli Lilly profit in the final quarter of 2024
Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...
Reuters7d
Eli Lilly and Co
Novo Nordisk defends next-gen obesity drug CagriSema, details new trial Future ... set to slow Eli Lilly investors and analysts said they want to hear details from the company on how exactly ...